A phase I pharmacodynamic study of the proteasome inhibitor PS-341.

被引：0
|
作者：
Thomas, JP
Adjei, A
Ehrlichman, C
Geiger, P
Haas, A
Arzoomanian, R
Alberti, D
Marnocha, R
Binger, K
Volkman, J
Feierabend, C
Tutsch, K
Adams, J
Eliot, P
Wilding, G
机构：
[1] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[2] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[3] Millenium Pharmaceut, Cambridge, MA USA
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
416
引用
收藏
页码：4549S / 4549S
页数：1
相关论文
共 50 条
  • [1] Clinical pharmacology of the proteasome inhibitor PS-341.
    Nix, DJ
    Pien, C
    Labutti, J
    Madden, T
    Adams, J
    Elliott, P
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3732S - 3732S
  • [2] Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341.
    Hideshima, T
    Mitsiades, C
    Akiyama, M
    Hayashi, T
    Chauhan, D
    Richardson, PG
    Schlossman, RL
    Podar, K
    Munshi, NC
    Mitsiades, N
    Anderson, KC
    BLOOD, 2002, 100 (11) : 814A - 814A
  • [3] Gene expression profiling in the prediction of response of multiple myeloma to the proteasome inhibitor PS-341.
    Shaughnessy, J
    Zhan, FH
    McCastlain, K
    Tian, EM
    Tricot, G
    BLOOD, 2002, 100 (11) : 390A - 390A
  • [4] Proteasome inhibition by PS-341: A phase I study.
    Hamilton, A
    Eder, JP
    Pavlick, A
    Clark, JW
    Chachoua, A
    Ryan, DP
    Farrell, K
    Wasserstrom, H
    Liebes, L
    Wright, J
    Elliott, P
    Adams, J
    Muggia, F
    CLINICAL CANCER RESEARCH, 2000, 6 : 4549S - 4549S
  • [5] Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.
    Papandreou, CN
    Pagliaro, L
    Millikan, R
    Daliani, D
    Herrmann, J
    Hong, Y
    Smith, M
    Adams, J
    Elliot, P
    Lightcap, E
    McCormack, T
    Pien, C
    Newman, R
    Logothetis, CJ
    CLINICAL CANCER RESEARCH, 1999, 5 : 3730S - 3730S
  • [6] The Hsp90 inhibitor 17-AAG sensitizes human leukemia cells to proteasome inhibitor PS-341.
    Yao, Q
    Kersey, JH
    BLOOD, 2003, 102 (11) : 622A - 623A
  • [7] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Orlowski, RZ
    Stinchcombe, TE
    Mitchell, BS
    Shea, TC
    Baldwin, AS
    Stahl, S
    Adams, J
    Esseltine, DL
    Elliott, PJ
    Pien, CS
    Guerciolini, R
    Anderson, JK
    Depcik-Smith, ND
    Bhagat, R
    Lehman, MJ
    Novick, SC
    O'Connor, OA
    Soignet, SL
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4420 - 4427
  • [8] Development of the proteasome inhibitor PS-341
    Adams, J
    ONCOLOGIST, 2002, 7 (01): : 9 - 16
  • [9] A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Aghajanian, C
    Soignet, S
    Dizon, DS
    Pien, CS
    Adams, J
    Elliott, PJ
    Sabbatini, P
    Miller, V
    Hensley, ML
    Pezzulli, S
    Canales, C
    Daud, A
    Spriggs, DR
    CLINICAL CANCER RESEARCH, 2002, 8 (08) : 2505 - 2511
  • [10] The proteasome inhibitor PS-341 in cancer therapy
    Teicher, BA
    Ara, G
    Herbst, R
    Palombella, VJ
    Adams, J
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2638 - 2645
12345